Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis

Objective

Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understanding of the epigenetic and genetic profile of LC, such knowledge has contributed little to improving therapeutics. This scenario, however, is likely to change soon because several specific cancer therapies, targeting molecules that are altered in cancer, are being developed or are already undergoing clinical trials. Thinking ahead, our proposal focuses, on the one hand, on validating novel and specific therapeutic strategies, with particular emphasis on discovering (epi)genetic alterations that could act as novel targets for therapies, and, on the other, on defining the (epi)genetic markers that could determine the efficacy response or resistance to targeted therapies as well as the acquired resistance of the tumours to therapy. To reach our goals, we have designed an integrative and interdisciplinary approach involving leading European clinical scientists of international renown with prominent preclinical and basic research groups using high throughput and state-of-the art platforms for genomics and gene expression analysis. To date, no such comprehensive information exists. The results will be of great value for the stratification of lung tumours according to their genetic background for tailored treatments. The development of an (epi)genetic-based therapeutic prediction model will hopefully set the basis for future tailored treatment of LC as well as of other epithelial cancers.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-HEALTH-2010-two-stage
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CP-FP - Small or medium-scale focused research project

Coordinator

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
EU contribution
€ 798 520,00
Address
AVENIDA GRAN VIA HOSPITALET 199-203
08908 L'Hospitalet De Llobregat
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (10)

My booklet 0 0